Time and cost savings through AI usage in drug discovery worldwide by scenario 2023
According to a survey among experts combined with an analysis of scientific publications, AI-enabled workflows could save up to 40 percent of time in bringing a new molecule for a difficult/poorly understood target to preclinical candidate (PCC) stage. Cost savings for such a molecule until preclinical candidate stage would be up to 30 percent. This statistic shows potential time and cost savings through AI usage in drug discovery worldwide as of 2023, by scenario.